Who makes LY2584702 Reference Formulation?

LY2584702 Reference Formulation is developed by Eli Lilly and Company.

What development phase is LY2584702 Reference Formulation in?

LY2584702 Reference Formulation is in Phase 1.

Last reviewed 2026-04-20 · How we verify

LY2584702 Reference Formulation

Eli Lilly and Company · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	LY2584702 Reference Formulation
Sponsor	Eli Lilly and Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Single Dose Study in Healthy Participants to Investigate the Safety and Absorption of LY2584702 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LY2584702 Reference Formulation CI brief — competitive landscape report
LY2584702 Reference Formulation updates RSS · CI watch RSS
Eli Lilly and Company portfolio CI